BIAL is a multinational pharmaceutical company headquartered in Porto, Portugal. Founded in 1914, BIAL has evolved from a local pharmaceutical company into a global innovator focused on neurological and immunological diseases. The company is particularly known for its breakthrough in Parkinson's disease treatment with opicapone. [1]
BIAL maintains a significant research and development operation in Portugal and collaborates with academic institutions worldwide to develop novel therapeutics for central nervous system disorders. [2]
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Opicapone (Ongentys) | COMT inhibitor | Parkinson's Disease | Approved | Commercial |
| BIA 28-6156 | Alpha-synuclein | Parkinson's Disease | Phase 2 | Clinical |
| BIA 324-003 | unspecified | Neurological | Preclinical | Research |
| BIA 342-232 | undisclosed | Immunology | Phase 1 | Clinical |
BIAL's research focuses on:
Opicapone is a once-daily COMT inhibitor approved as an adjunct therapy to levodopa/carbidopa for Parkinson's disease patients experiencing end-of-dose motor fluctuations:
BIAL's alpha-synuclein antibody program for Parkinson's disease:
Key References:
Motor Fluctuations
Ferreira JJ et al. Opicapone for the treatment of Parkinson's disease: A review of Phase III studies. Lancet Neurology. 2016. ↩︎
Poewe W et al. BIA 28-6156: A novel alpha-synuclein antibody for Parkinson's disease. Movement Disorders. 2022. ↩︎